文献速递帕金森病与运动障碍

帕金森病中LRRK2功能缺失变异的频率

Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease.
PubMed 文献 · JAMA Neurol · 2018-01-01

该研究分析超过23000人的病例对照队列二代测序数据,发现LRRK1和LRRK2功能缺失变异在帕金森病病例与对照中的频率均很低,且与帕金森病风险无显著关联;淋巴母细胞样细胞系显示杂合功能缺失变异携带者LRRK2蛋白水平较野生型等位基因降低约一半。

要点

  • LRRK1功能缺失变异在病例中占0.205%、对照中占0.139%,比值比1.48(95%CI 0.45-4.44,P=0.49)。
  • LRRK2功能缺失变异在病例中占0.117%、对照中占0.087%,比值比1.48(95%CI 0.63-3.50,P=0.36)。
  • LRRK1或LRRK2单倍剂量不足既不是帕金森病的原因,也不具有保护作用。

核心结论

  • LRRK1或LRRK2单倍剂量不足既不是帕金森病的原因,也不具有保护作用。
  • 激酶抑制或等位基因特异性靶向突变LRRK2仍是帕金森病可行的治疗策略。

研究设计与样本

  • 研究分析了一个大型病例对照队列(超过23000人)的二代测序数据,检测LRRK1和LRRK2功能缺失变异。
  • 数据来自5个不同站点和5个不同数据集,包括临床诊断的帕金森病病例和神经学正常对照个体。
  • 数据收集时间为2012年至2017年。

主要发现

  • 在11095例帕金森病病例和12615例对照中,LRRK1功能缺失变异在病例中占0.205%、在对照中占0.139%(比值比1.48;标准误0.571;95%CI 0.45-4.44;P=0.49)。
  • LRRK2功能缺失变异在病例中占0.117%、在对照中占0.087%(比值比1.48;标准误0.431;95%CI 0.63-3.50;P=0.36)。
  • 所有关联检验均提示LRRK1或LRRK2变异与帕金森病无关联。
  • 对来自数名杂合功能缺失变异携带者的淋巴母细胞样细胞系进一步分析发现,与野生型等位基因相比,LRRK2蛋白水平如预期降低约一半。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pathogenic variants in LRRK2 are a relatively common genetic cause of Parkinson disease (PD). Currently, the molecular mechanism underlying disease is unknown, and gain and loss of function (LOF) models of pathogenesis have been postulated. LRRK2 variants are reported to result in enhanced phosphorylation of substrates and increased cell death. However, the double knockout of Lrrk2 and its homologue Lrrk1 results in neurodegeneration in a mouse model, suggesting that disease may occur by LOF. Because LRRK2 inhibitors are currently in development as potential disease-modifying treatments in PD, it is critical to determine whether LOF variants in LRRK2 increase or decrease the risk of PD. OBJECTIVE: To determine whether LRRK1 and LRRK2 LOF variants contribute to the risk of developing PD. DESIGN, SETTING, AND PARTICIPANTS: To determine the prevailing mechanism of LRRK2-mediated disease in human populations, next-generation sequencing data from a large case-control cohort (>23 000 individuals) was analyzed for LOF variants in LRRK1 and LRRK2. Data were generated at 5 different sites and 5 different data sets, including cases with clinically diagnosed PD and neurologically normal control individuals. Data were collected from 2012 through 2017. MAIN OUTCOMES AND MEASURES: Frequencies of LRRK1 and LRRK2 LOF variants present in the general population and compared between cases and controls. RESULTS: Among 11 095 cases with PD and 12 615 controls, LRRK1 LOF variants were identified in 0.205% of cases and 0.139% of controls (odds ratio, 1.48; SE, 0.571; 95% CI, 0.45-4.44; P = .49) and LRRK2 LOF variants were found in 0.117% of cases and 0.087% of controls (odds ratio, 1.48; SE, 0.431; 95% CI, 0.63-3.50; P = .36). All association tests suggested lack of association between LRRK1 or LRRK2 variants and PD. Further analysis of lymphoblastoid cell lines from several heterozygous LOF variant carriers found that, as expected, LRRK2 protein levels are reduced by approximately half compared with wild-type alleles. CONCLUSIONS AND RELEVANCE: Together these findings indicate that haploinsufficiency of LRRK1 or LRRK2 is neither a cause of nor protective against PD. Furthermore, these results suggest that kinase inhibition or allele-specific targeting of mutant LRRK2 remain viable therapeutic strategies in PD.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Blauwendraat C, Reed X, Kia DA, et al. Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA Neurol. 2018. PMID: 30039155. doi:10.1001/jamaneurol.2018.1885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。